X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1843) 1843
Publication (436) 436
Book Review (35) 35
Book Chapter (15) 15
Book / eBook (13) 13
Conference Proceeding (3) 3
Dissertation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (1220) 1220
humans (934) 934
index medicus (924) 924
male (589) 589
atp (503) 503
pharmacology & pharmacy (482) 482
purinergic p2 receptor antagonists (472) 472
rats (471) 471
adenosine triphosphate - pharmacology (401) 401
neurosciences (384) 384
receptors, purinergic p2 - metabolism (336) 336
mice (310) 310
female (269) 269
adenosine triphosphate - analogs & derivatives (254) 254
adenosine triphosphate - metabolism (241) 241
receptors, purinergic p2 - physiology (238) 238
dose-response relationship, drug (222) 222
adenosine (221) 221
platelet aggregation inhibitors - therapeutic use (211) 211
extracellular atp (205) 205
purinergic receptors (194) 194
in vitro techniques (189) 189
inflammation (189) 189
ticlopidine - analogs & derivatives (189) 189
cells, cultured (182) 182
cell biology (181) 181
p2x receptors (175) 175
receptors (171) 171
p2x receptor (169) 169
signal transduction (167) 167
rats, sprague-dawley (163) 163
activation (162) 162
biochemistry & molecular biology (159) 159
platelet aggregation inhibitors - pharmacology (158) 158
receptors, purinergic p2 - drug effects (158) 158
clopidogrel (157) 157
physiological aspects (153) 153
biomedicine (151) 151
rats, wistar (147) 147
ticlopidine - therapeutic use (147) 147
physiology (142) 142
calcium - metabolism (141) 141
receptors, purinergic p2y12 (141) 141
papers (139) 139
nucleotides (136) 136
receptors, purinergic p2x7 - metabolism (131) 131
receptors, purinergic p2 - genetics (130) 130
analysis (128) 128
neurons (128) 128
research (128) 128
purinergic p2 receptor agonists (125) 125
rodents (125) 125
pharmacology/toxicology (123) 123
article (121) 121
disease models, animal (118) 118
platelet aggregation - drug effects (117) 117
mice, inbred c57bl (115) 115
p2y receptor (115) 115
pyridoxal phosphate - analogs & derivatives (114) 114
receptor (114) 114
adenosine triphosphate (113) 113
expression (113) 113
pyridoxal phosphate - pharmacology (112) 112
p2x (111) 111
human physiology (110) 110
p2y (110) 110
cells (107) 107
neuropathic pain (107) 107
suramin - pharmacology (107) 107
proteins (104) 104
signal transduction - drug effects (102) 102
apoptosis (101) 101
rat (101) 101
adenosine diphosphate - pharmacology (99) 99
adenosine - pharmacology (97) 97
adenosine - analogs & derivatives (95) 95
cancer research (95) 95
middle aged (95) 95
p2x7 receptor (95) 95
blood platelets - drug effects (94) 94
prasugrel hydrochloride (94) 94
sensory neurons (94) 94
research article (93) 93
p2 receptors (91) 91
medicine (89) 89
signal transduction - physiology (89) 89
purinoceptors (88) 88
release (88) 88
hematology (87) 87
immunology (86) 86
aspirin (84) 84
original (84) 84
peripheral vascular disease (84) 84
pharmacology (84) 84
review (84) 84
uridine triphosphate - pharmacology (84) 84
adenosine triphosphate - physiology (83) 83
pain (83) 83
calcium (82) 82
p2y receptors (82) 82
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 2014, Volume 505, Issue 7482, pp. 223 - 228
Traumatic brain injury (TBI) is increasingly appreciated to be highly prevalent and deleterious to neurological function(1,2). At present, no effective... 
BIOMARKERS | GREEN FLUORESCENT PROTEIN | HEAD-INJURY | INSERTION | STERILE INFLAMMATION | FLUID | CORTEX | MULTIDISCIPLINARY SCIENCES | IN-VIVO | MICE | RELEASE | Encephalitis - prevention & control | Neuroprotective Agents - therapeutic use | Reactive Oxygen Species - metabolism | Brain Injuries - drug therapy | Humans | Astrocytes - pathology | Brain Injuries - complications | Male | Intracranial Hemorrhages - diagnosis | Microglia - physiology | Encephalitis - drug therapy | Glasgow Coma Scale | Purinergic P2 Receptor Antagonists - pharmacology | Encephalitis - complications | Cell Death - drug effects | Neuroprotective Agents - administration & dosage | Disease Models, Animal | Microglia - cytology | Glutathione - therapeutic use | Skull - metabolism | Meninges - pathology | Microglia - drug effects | Neutrophils - drug effects | Neutrophils - physiology | Encephalitis - pathology | Rats | Purinergic P2 Receptor Antagonists - therapeutic use | Meninges - drug effects | Rats, Sprague-Dawley | Brain Injuries - diagnosis | Brain - drug effects | Antioxidants - therapeutic use | Animals | Glutathione - administration & dosage | Receptors, Purinergic P2 - metabolism | Antioxidants - administration & dosage | Brain - pathology | Receptors, Purinergic P2X7 - metabolism | Purinergic P2 Receptor Antagonists - administration & dosage | Mice | Administration, Topical | Brain Injuries - pathology | Intracranial Hemorrhages - complications | Brain | Medical examination | Cell death | Physiological aspects | Skull | Models | Meninges | Observations | Injuries | Brain damage | Emergency medical care | Head injuries | Rodents
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2012, Volume 367, Issue 14, pp. 1297 - 1309
Journal Article
PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 5, p. e19983
Background: After ischemia of the CNS, extracellular adenosine 5'-triphosphate (ATP) can reach high concentrations due to cell damage and subsequent increase... 
EXTRACELLULAR ATP | TUMOR-NECROSIS-FACTOR | MICROGLIAL ACTIVATION | TRANSIENT FOREBRAIN ISCHEMIA | BRAIN-INJURY | IL-1-BETA RELEASE | P2X RECEPTORS | MULTIDISCIPLINARY SCIENCES | CEREBRAL-ARTERY OCCLUSION | PURINERGIC MODULATION | NUCLEUS-ACCUMBENS | Immunohistochemistry | In Situ Nick-End Labeling | Rats, Inbred SHR | Infarction, Middle Cerebral Artery - physiopathology | Pyridoxal Phosphate - pharmacology | Pyridoxal Phosphate - therapeutic use | Recovery of Function - drug effects | Motor Activity - drug effects | Rats | Stroke - complications | Male | Purinergic P2 Receptor Antagonists - therapeutic use | Electroencephalography | Stroke - drug therapy | Stroke - physiopathology | Magnetic Resonance Imaging | Rotarod Performance Test | Animals | Time Factors | Infarction, Middle Cerebral Artery - complications | Purinergic P2 Receptor Antagonists - pharmacology | Cell Death - drug effects | Pyridoxal Phosphate - analogs & derivatives | Hypertension | Permeability | Ischemia | Occlusion | Neurosciences | Nuclear magnetic resonance--NMR | Central nervous system | Membrane permeability | Recovery of function | Confocal microscopy | Nervous system | Confocal | Kinases | Recovery | Proteins | Signal transduction | Receptors | Toxicology | Neurodegeneration | Cerebral blood flow | Rodents | Tumor necrosis factor-TNF | Purine P2 receptors | Degeneration | Inhibition | Stroke | Astrocytes | Inflammation | Pharmacology | Frequencies | Hypoglycemia | Studies | Neurology | Magnetic resonance imaging | Microscopy | Magnetic permeability | Neural networks | ATP | Scanning microscopy | Apoptosis | Veins & arteries | Nuclear magnetic resonance | NMR
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2013, Volume 8, Issue 4, p. e59778
It is important to understand the mechanisms that regulate macrophage activation to establish novel therapies for inflammatory diseases, such as sepsis; a... 
EXTRACELLULAR ATP | UNITED-STATES | NITRIC-OXIDE PRODUCTION | IL-1-BETA RELEASE | MULTIDISCIPLINARY SCIENCES | T-CELL-ACTIVATION | SEPTIC SHOCK | VESICULAR NUCLEOTIDE TRANSPORTER | SEPSIS | P2Y-LIKE RECEPTORS | ALTERNATIVE ACTIVATION | Humans | Adenosine Triphosphate - secretion | Male | Autocrine Communication - drug effects | Shock, Septic - immunology | Exocytosis - drug effects | Shock, Septic - metabolism | Ascitic Fluid - metabolism | Interleukin-6 - blood | Suramin - therapeutic use | Shock, Septic - drug therapy | Suramin - analogs & derivatives | Purinergic P2 Receptor Antagonists - pharmacology | Interleukin-6 - metabolism | Macrophages - immunology | Suramin - pharmacology | Shock, Septic - chemically induced | Purinergic P2 Receptor Antagonists - therapeutic use | Macrophages - cytology | Ascitic Fluid - drug effects | Macrophages - metabolism | Animals | Receptors, Purinergic P2 - metabolism | Lipopolysaccharides - pharmacology | Cell Line, Tumor | Interleukin-6 - biosynthesis | Macrophages - drug effects | Mice | Macrophage Activation - drug effects | Infection | Cytokines | Macrophages | Mitogens | Polarization | Lung cancer | Medical services | Inflammatory response | Activation | Drug development | Exocytosis | Positive feedback | Cytosol | Inflammatory diseases | Lipopolysaccharides | Interleukin 6 | Receptors | Elevation | Cell activation | Rodents | Bacteria | Pretreatment | Autocrine signalling | Pharmaceutical sciences | Adenosine triphosphate | Spleen | Immune response | Dendritic cells | Mortality | Medical treatment | Interleukin 12 | Tumor necrosis factor-α | Monocytes | Sepsis | ATP | Transporter | Peritoneum
Journal Article